Outcomes in Patients with Interstitial Lung Disease Receiving Programmed Cell Death Protein 1 (PD-1) Inhibitors

被引：0
|
作者：
Dobre, I. [1 ]
Frank, A. J. [2 ]
D'Silva, K. M. [2 ]
Okin, D. [2 ]
Sharma, A. [2 ]
Montesi, S. B. [2 ]
机构：
[1] Queens Univ, Sch Med, Kingston, ON, Canada
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7795
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study
    Tian, Yaru
    Lu, Shuangqing
    Sun, Yulan
    Tang, Xiaoyong
    Sun, Zhuoran
    Zhao, Ke
    Du, Guochang
    Li, Wanjing
    Zhu, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
    Dehghani, Tannaz
    Shahrjerdi, Alireza
    Kahrizi, Mohammad Saeed
    Soleimani, Elnaz
    Ravandeh, Saeideh
    Merza, Muna S.
    Rahnama, Negin
    Ebrahimzadeh, Farnoosh
    Bakhshesh, Morteza
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 246
  • [33] Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics
    Cassol, Clarissa A.
    Owen, Dwight
    Kendra, Kari
    Braga, Juarez R.
    Frankel, Wendy L.
    Arnold, Christina A.
    HISTOPATHOLOGY, 2020, 77 (02) : 240 - 249
  • [34] Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
    T. Mocan
    Z. Sparchez
    R. Craciun
    C. N. Bora
    D. C. Leucuta
    Clinical and Translational Oncology, 2019, 21 : 702 - 712
  • [35] Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
    Mocan, T.
    Sparchez, Z.
    Craciun, R.
    Bora, C. N.
    Leucuta, D. C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06): : 702 - 712
  • [36] The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients An updated systematic review and meta-analysis
    Shang, Heli
    Zhang, Zewen
    Feng, Alei
    Yang, Xiaowei
    Zhang, Shuisheng
    Zhao, Yi
    Zhu, Qingshan
    Mao, Yantao
    Liu, Kun
    Tian, Yuan
    MEDICINE, 2019, 98 (30)
  • [37] Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
    Guzik, Katarzyna
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Magiera, Katarzyna
    Musielak, Bogdan
    Torner, Ricarda
    Skalniak, Lukasz
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) : 5857 - 5867
  • [38] Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment
    Jomrich, Gerd
    Kollmann, Dagmar
    Ramazanova, Dariga
    Ristl, Robin
    Grose, Richard P.
    Ilhan-Mutlu, Ayseguel
    Preusser, Matthias
    Fassnacht, Christina
    Tsai, Yi-Chien
    Guenova, Emmanuella
    Schoppmann, Sebastian F.
    EJSO, 2022, 48 (02): : 383 - 390
  • [39] Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors
    Tang, Manyun
    Dang, Peizhu
    Liu, Tong
    Yang, Kun
    Wang, Yifei
    Tse, Gary
    Liu, Hui
    Liu, Yufeng
    Chan, Jeffrey Shi Kai
    Liu, Chang
    Li, Guoliang
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 407
  • [40] Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
    Pezeshki, Parmida Sadat
    Mahdavi Sharif, Pouya
    Rezaei, Nima
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (12) : 1575 - 1590
12345